Inhibikase Therapeutics discloses CFO Lees-Rolfe's compensation: $345K salary, 90K option

Inhibikase Therapeutics, Inc.

Base salary of $345,000 per annum with discretionary annual target bonus of 30% of base.
Initial stock option for 90,000 shares at $2.16, vesting in three equal annual installments.
Non-CIC termination severance: 9 months base salary plus COBRA reimbursement for 9 months.
CIC termination (within 12 months post-change): 12 months base salary lump sum, full equity vesting, one-time Target Bonus.
Employment Agreement effective April 1, 2024; role as Chief Financial Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.